Media stories about Nektar Therapeutics (NASDAQ:NKTR) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.1150612409564 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Stephen K. Doberstein Sells 43,677 Shares of Nektar Therapeutics (NKTR) Stock (americanbankingnews.com)
- Nektar Therapeutics (NKTR) CEO Howard W. Robin Sells 83,333 Shares (americanbankingnews.com)
- Advice by Analysts to Buy Healthcare Stock: Nektar Therapeutics (NKTR) – Street Observer (press release) (streetobserver.com)
- Notable Friday Option Activity: NKTR, PANW, SKX – Nasdaq (nasdaq.com)
- $114.14 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter (americanbankingnews.com)
A number of analysts have recently commented on the company. Mizuho assumed coverage on Nektar Therapeutics in a report on Tuesday, September 26th. They issued a “buy” rating and a $30.00 price target on the stock. ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub lowered Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a report on Friday, August 18th. Finally, Evercore ISI assumed coverage on Nektar Therapeutics in a report on Thursday, August 17th. They issued an “in-line” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.80.
Shares of Nektar Therapeutics (NASDAQ NKTR) opened at 23.27 on Wednesday. The company’s 50-day moving average price is $21.98 and its 200 day moving average price is $20.41. The company’s market cap is $3.64 billion. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $25.02.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The business had revenue of $34.60 million during the quarter, compared to the consensus estimate of $33.64 million. During the same period in the previous year, the business posted ($0.36) EPS. Nektar Therapeutics’s revenue was up 5.5% compared to the same quarter last year. Equities analysts predict that Nektar Therapeutics will post ($0.98) earnings per share for the current year.
In related news, CAO Jillian B. Thomsen sold 2,648 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total value of $51,159.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Lutz Lingnau sold 30,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $20.76, for a total transaction of $622,800.00. Following the completion of the transaction, the director now directly owns 53,450 shares in the company, valued at approximately $1,109,622. The disclosure for this sale can be found here. In the last ninety days, insiders sold 624,903 shares of company stock worth $14,170,140. 5.44% of the stock is owned by insiders.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.